ICD-10 Code Z08: encounter for follow-up after malignant neoplasm

Key Takeaways

ICD-10 Code Z08 is a billable ICD-10-CM code for encounters after completed malignant neoplasm treatment, valid for FY2026

Always report companion codes: Z85.- (personal history of malignant neoplasm) and Z90.- (acquired absence of organs) when applicable

Z08 applies only after treatment is fully completed; using it during active treatment or for non-malignant conditions is a common denial trigger

Pabau’s claims management software helps oncology practices apply Z08 accurately, attach companion codes, and submit clean claims through Claim.MD

ICD-10 Code Z08: definition and billable status

Oncology coders face a specific documentation challenge: once a patient’s cancer treatment ends, the visits don’t stop. Surveillance, follow-up imaging, and post-treatment examinations continue for months or years, and each one needs a code that accurately reflects the encounter’s purpose. handles exactly that scenario, and getting it right keeps claims clean and audit-ready. You can look up the official code entry through the CDC/NCHS ICD-10-CM web tool, which is updated each fiscal year.

ICD-10 Code Z08 carries the full description: Encounter for follow-up examination after completed treatment for malignant neoplasm. It is a billable, specific code, meaning it can stand as a reportable diagnosis for reimbursement purposes without requiring a more granular subcategory. The code sits within the Z00-Z13 chapter (Persons encountering health services for examinations) and is confirmed valid for dates of service on or after October 1, 2025 under the FY2026 ICD-10-CM code set, as maintained by the Centers for Medicare and Medicaid Services (CMS) and the National Center for Health Statistics (NCHS). For a broader view of ICD-10 diagnostic coding structure, the ICD-10 diagnostic coding reference covers related classification principles.

When to use ICD-10 Code Z08

Z08 applies to a narrow, well-defined clinical scenario: the patient has completed treatment for a confirmed malignant neoplasm and presents for a follow-up or surveillance encounter. “Completed treatment” includes chemotherapy, radiation, surgery, immunotherapy, or a combination, provided no active treatment is ongoing at the time of the visit.

• Post-chemotherapy surveillance: patient has finished a defined chemotherapy course and attends for follow-up labs, imaging review, or physical examination
• Post-surgical oncology follow-up: patient returns after curative-intent surgery (e.g. mastectomy, colectomy) with no residual disease currently under treatment
• Post-radiation monitoring: encounter occurs after completion of a radiation course with the purpose of assessing response or detecting recurrence
• Routine surveillance visits: scheduled check-ups during the post-treatment watchful-waiting period for cancers such as breast, colorectal, prostate, or thyroid malignancies
• Annual cancer surveillance examinations: long-term follow-up years after remission, where the visit purpose is monitoring rather than active treatment

Z08 is not appropriate when active treatment is still in progress, when the patient presents for a new primary cancer, or when the encounter involves a benign or unspecified neoplasm. Those scenarios require different ICD-10-CM codes. The World Health Organization’s ICD-10 browser confirms that Z-category codes in this range are reserved for health service contacts that are not related to current illness or injury.

Z08 vs Z09: key differences for coders

The single most common coding error in post-treatment follow-up billing is using Z08 and Z09 interchangeably. These codes cover distinct patient populations, and payer systems are built to detect misapplication. The core distinction: Z08 is for malignant neoplasm follow-up; Z09 is for all other completed-treatment follow-up. See additional ICD-10 diagnostic code guidance for how the Z-code chapter handles analogous classification distinctions across condition categories.

Oncology follow-up coding guidelines and companion codes for Z08

The ICD-10-CM Official Guidelines for Coding and Reporting, maintained jointly by CMS and NCHS, specify two “use additional code” instructions that coders must follow when reporting Z08. These are not optional annotations – omitting them is a documentation and compliance gap that can prompt payer queries or audits. Applying them correctly is part of medical billing compliance for oncology practices.

Z85.- personal history of malignant neoplasm

Always report a Z85.- code alongside Z08 to identify the specific malignancy the patient was previously treated for. The Z85 category breaks down by body site and histology, so the coder selects the appropriate fourth or fifth character based on the patient’s medical record. For example, Z85.3 covers personal history of malignant neoplasm of breast; Z85.038 covers sigmoid colon history.

Z90.- acquired absence of organs

When the patient’s treatment included organ removal as part of curative intent (mastectomy, nephrectomy, colectomy, etc.), also report the applicable Z90.- code to document the surgical absence. This is not required for every Z08 encounter, only when the medical record documents organ absence that is clinically relevant to the follow-up visit.

The AAPC’s ICD-10-CM code lookup provides searchable access to the full Z85 and Z90 subcategory lists. Review the ICD-10-CM coding guidelines through the ICD-10-CM coding guidelines context for related Z-code application patterns.

Documentation requirements for Z08

Medical record documentation must support Z08 on three specific points. Payers increasingly request records on post-treatment cancer surveillance claims, and documentation gaps are the leading audit trigger for this code category. Strong HIPAA-compliant documentation practices reduce this risk considerably.

• Treatment completion confirmed: the note must state that the patient’s primary cancer treatment (chemotherapy, radiation, surgery, or combination) is finished, not paused or ongoing
• Prior malignancy identified: the specific type and site of the original cancer must be documented to support Z85.- code selection
• Encounter purpose is follow-up, not active treatment: the clinical note must reflect a surveillance or monitoring purpose; if any new treatment is ordered, Z08 no longer applies to that visit
• Organ absence documented (if applicable): surgical notes or prior-visit records should confirm organ removal to support Z90.- reporting
• No evidence of recurrence stated, or recurrence noted separately: if recurrence is detected during the visit, code the active malignancy, not Z08

One practical documentation note: if the oncologist documents “no evidence of disease” (NED) or “in remission” with a surveillance plan, that phrasing is typically sufficient to support Z08. Language implying active disease management signals to auditors that the encounter involved treatment, not post-treatment follow-up.

CPT codes commonly used with Z08

ICD-10 Code Z08 is paired with procedure codes to complete the claim. The CPT codes used with Z08 depend on the nature of the follow-up encounter: a simple office visit uses E/M codes, while specialty surveillance may involve additional procedures. The American Medical Association (AMA) publishes the CPT code set that governs procedure/diagnosis pairing. Understanding the medical billing workflow for oncology encounters helps practices pair these correctly from intake through claim submission.

Note: specific CPT-to-ICD-10 crosswalk details should be verified against current AMA CPT guidelines and individual payer medical necessity policies, as pairing requirements vary by payer and specialty context.

MS-DRG mapping and billing for Z08

In inpatient and facility billing settings, ICD-10 Code Z08 contributes to MS-DRG (Medicare Severity-Diagnosis Related Group) assignment alongside principal and secondary diagnoses. For outpatient oncology follow-up, Z08 is most commonly reported on professional claims (CMS-1500 / 837P), where it functions as a primary or secondary diagnosis depending on the encounter structure.

Current MS-DRG assignments linked to Z08 should be verified against the CMS MS-DRG Definitions Manual for the applicable fiscal year, as group assignments shift with annual code updates. Practices submitting claims electronically through a clearinghouse route Z08-coded claims through standard 837P transaction sets. Pabau integrates with the Claim.MD clearinghouse integration to submit oncology follow-up claims, verify patient eligibility, and receive electronic remittance advice for Z08-coded encounters. The electronic remittance advice process is particularly important for Z08 claims where payer-specific coverage policies may result in adjustment codes the billing team needs to act on.

Payer-specific coverage policies for post-malignancy surveillance may be governed by Local Coverage Determinations (LCDs) or National Coverage Determinations (NCDs) published by CMS. The CMS ICD code lists and individual MAC portals are the authoritative sources for verifying Z08 coverage under Medicare. For practices using Pabau, the electronic claims clearinghouse connection handles real-time eligibility verification ahead of Z08-coded visits, reducing the risk of submitting to a plan that doesn’t cover the specific surveillance service.

Streamline oncology follow-up billing

Pabau’s claims management tools help oncology and multi-specialty practices apply Z08 accurately, attach companion codes, and submit clean claims through Claim.MD. See how it works for your practice.

Book a demo

Common coding mistakes to avoid with Z08

Z08 is a narrowly defined code, and its boundaries are where most denials originate. The errors below account for the majority of Z08-related claim rejections and audit findings in oncology billing. Proactive denial management in oncology billing starts with catching these before submission.

• Using Z08 during active treatment: if the patient is receiving any form of active cancer therapy (chemotherapy, targeted therapy, immunotherapy, radiation), the encounter should be coded to reflect the treatment context, not Z08
• Confusing Z08 with Z09: applying Z08 to a follow-up for a non-malignant condition (post-appendectomy, post-pneumonia) is an incorrect code assignment; Z09 covers those scenarios
• Omitting the Z85.- companion code: submitting Z08 without a Z85.- personal history code leaves the claim without the required additional code; some payers may deny or request documentation on this basis
• Using Z08 for benign or unspecified neoplasm follow-up: Z08 specifically requires a prior malignant neoplasm diagnosis; benign tumor follow-up requires different ICD-10-CM codes
• Coding Z08 when recurrence is found during the visit: if the follow-up visit results in identification of a new or recurrent malignancy, code the active cancer diagnosis; Z08 is no longer the correct primary code
• Selecting Z85.- at too low a specificity level: Z85.9 (personal history of unspecified malignant neoplasm) is often avoidable; use the most specific Z85 subcategory the documentation supports

How Pabau supports oncology follow-up coding

No competing resource in the ICD-10 code reference space covers how practice management software directly supports Z08 accuracy. This is where workflow matters: accurate Z08 coding depends on documentation captured during the encounter, not fixed after the fact during coding review. Pabau’s claims management software integrates ICD-10 code search directly into the clinical documentation workflow, so clinicians and coders are working from the same record.

For oncology and multi-specialty practices managing post-treatment surveillance schedules, this integration means companion code prompts (Z85.-, Z90.-) can be built into encounter templates, reducing the chance of omission. Claims flow through Claim.MD’s network of over 4,000 US payers via the 837P transaction format, with real-time eligibility checks confirming coverage before the visit. Electronic remittance advice (835 files) returned through the integration gives billing teams the denial reason codes they need to appeal or correct Z08-related claim adjustments quickly.

Managing revenue cycle management for oncology follow-up involves more than submitting a single code correctly. It means tracking surveillance visit schedules, coordinating documentation between clinical and billing teams, and maintaining audit-ready records across the patient’s full post-treatment history. Pabau’s clinical documentation and billing tools are designed to support that full-cycle picture, not just the claim submission step.

Conclusion

Post-treatment cancer surveillance is among the highest-volume encounter types in oncology billing, and Z08 is the code that makes those visits reimbursable. The code is straightforward in concept but demands precision in execution: treatment must be confirmed complete, companion codes Z85.- and Z90.- must be applied correctly, and the encounter documentation must clearly reflect surveillance rather than active treatment.

Pabau’s integrated claims management and Claim.MD clearinghouse connection give oncology practices the workflow structure to apply Z08 consistently and submit clean claims on the first pass. To see how it works for your billing team, book a demo.

Continue your research

Need to understand how claim denials are handled after Z08 submission? Denial codes in medical billing covers the most common CARC reason codes and how to appeal them effectively.

Want to see how a medical claims clearinghouse works in practice? Medical claims clearinghouse guide explains how 837P claims flow from practice to payer and back.

Looking for clean claim submission best practices? Clean claim checklist outlines the fields, codes, and checks that prevent first-pass rejections across all claim types.

Frequently Asked Questions